Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

The Lucrative Growth of Investing in Intuitive Surgical

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
IT-Healthcare
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Investing in Intuitive Surgical (NASDAQ: ISRG) has been a game-changer for those who took the leap 10 years ago. With $1000 invested back then, it would now be worth an impressive $8,078.92, thanks to the stock’s current price of $389.67. This translates to an annualized outperformance of 12.52% and an average return of 23.17% over the past decade, showcasing the power of compounded returns on wealth accumulation.

For those who jumped on board in 2014 with a $1000 investment, the growth would be even more staggering, reaching $2,434,188.68 by March 13, 2024, a remarkable return of 540.6%. The current price per share stands at $270.46, indicating the company’s consistent growth trajectory.

Intuitive Surgical, Inc. is a pioneer in robotic-assisted products like the da Vinci surgical system, revolutionizing minimally invasive surgery and improving clinical outcomes. With a market capitalization of $138.12 billion, the company’s stock price is on an upward trend, with analysts forecasting an average price target of $416.89, representing a 6.39% upside potential.

In conclusion, investing in Intuitive Surgical has proven to be a lucrative decision, with substantial returns and strong market performance over the past decade.

Intuitive Surgical Inc. (ISRG) Stock Price Analysis: Potential for Growth Despite Recent Drop

On March 13, 2024, Intuitive Surgical Inc. (ISRG) experienced a slight drop in its stock price, closing at $382.99. Despite this decrease, ISRG is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating strong price momentum for the company.

The price of ISRG shares decreased by $6.41, or 1.65%, since the market last closed. However, in after-hours trading, the stock has risen by $0.91, showing some potential for recovery.

Investors and analysts will be keeping a close eye on ISRG in the coming days to see if the stock can maintain its upward momentum and continue to perform well. With its position near the top of its 52-week range, ISRG may have the potential for further growth and profitability in the future.

Overall, while the drop in ISRG’s stock price on March 13 may be concerning to some investors, the company’s strong price momentum and position above its 200-day simple moving average suggest that there may still be opportunities for growth and success in the future.

Intuitive Surgical Inc. (ISRG) Stock Performance Analysis: Strong Revenue Growth and Increased Net Income for 2024

On March 13, 2024, Intuitive Surgical Inc. (ISRG) stock showed strong performance based on the latest financial data. The company reported total revenue of $7.12 billion for the past year, which represents a 14.49% increase compared to the previous year. In the fourth quarter alone, ISRG generated $1.93 billion in revenue, marking a 10.59% increase from the previous quarter.

Net income for ISRG was reported at $1.80 billion for the past year and $606.20 million for the fourth quarter. This indicates a significant 35.98% increase in net income compared to the previous year. However, net income remained flat compared to the previous quarter.

Earnings per share (EPS) for ISRG were reported at $5.03 for the past year and $1.69 for the fourth quarter. This represents a 37.72% increase in EPS compared to the previous year, but EPS held flat compared to the previous quarter.

Overall, ISRG stock showed positive performance on March 13, 2024, with strong revenue growth and significant increases in net income and earnings per share compared to the previous year. Investors may view these financial results as a positive indicator of the company’s financial health and potential for future growth.

Tags: ISRG
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Pharmaceutical Trading online

Inventiva to Unveil Results of LEGEND Phase IIa Trial on Lanifibranor and Empagliflozin Combination Therapy

DrugRetailers Trading online

Leadership Changes at Fossil Group Inc A Strategic Shift Towards Growth and Transformation

scPharmaceuticals Reports Strong Fourth Quarter 2023 Financial Results

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com